Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Cellectis SA

Healthcare US CLLS

2.82USD
-0.16(5.37%)

Last update at 2026-06-22T20:00:00Z

Day Range

2.792.86
LowHigh

52 Week Range

1.335.48
LowHigh

Fundamentals

  • Previous Close 2.98
  • Market Cap412.25M
  • Volume21477
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-21.75000M
  • Revenue TTM79.59M
  • Revenue Per Share TTM0.79
  • Gross Profit TTM 79.59M
  • Diluted EPS TTM-0.67

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -74.89101M -36.76100M -116.46400M -98.60100M -97.48300M
Minority interest 0.00000M 0.00000M 7.38M 7.89M 10.91M
Net income -67.80215M -36.76100M -101.05900M -98.68800M -86.28000M
Selling general administrative 8.60M 8.42M 8.12M 17.49M 37.87M
Selling and marketing expenses - - 2.01M 3.11M 6.33M
Gross profit 53.05M 32.32M -6.66400M 17.40M 37.67M
Reconciled depreciation 20.06M 19.85M 18.52M 18.43M 16.57M
Ebit -40.48287M -29.30800M -111.16000M -108.10100M -102.00700M
Ebitda -20.35880M -9.46200M -92.63700M -89.66600M -85.43700M
Depreciation and amortization 20.12M 19.85M 18.52M 18.43M 16.57M
Non operating income net other - - - - -
Operating income -40.48287M -59.55400M -97.30200M -89.66600M -85.43700M
Other operating expenses 113.66M 101.06M 98.06M 108.84M 159.39M
Interest expense 8.13M 7.45M 5.31M 3.79M 5.34M
Tax provision -0.42300M 0.00000M 0.37M 0.09M -
Interest income 9.50M 11.28M 3.61M 1.12M 0.74M
Net interest income 1.39M 3.83M -2.81200M -8.93500M -4.16100M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -7.08887M -6.44700M 0.37M 0.09M -11.20300M
Total revenue 73.17M 41.51M 0.76M 19.17M 73.95M
Total operating expenses 93.53M 91.88M 90.64M 107.06M 123.11M
Cost of revenue 20.12M 9.18M 7.42M 1.77M 36.27M
Total other income expense net -34.40814M 22.79M -19.16200M -8.93500M -12.04600M
Discontinued operations - - - -15.34500M -28.35800M
Net income from continuing ops -67.59300M -36.76100M -116.83500M -98.68800M -125.10700M
Net income applicable to common shares - - - -106.13900M -114.19700M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 324.72M 383.54M 334.27M 261.22M 382.08M
Intangible assets 0.54M 1.11M 0.67M 0.72M 1.85M
Earning assets - - - - -
Other current assets 5.38M 3.73M 6.06M 9.08M 9.66M
Total liab 248.82M 252.51M 249.57M 135.28M 145.60M
Total stockholder equity 75.90M 131.03M 84.69M 117.97M 221.29M
Deferred long term liab - - - - -
Other current liab 13.51M 22.20M 12.09M 28.52M 14.60M
Common stock 5.90M 5.89M 4.37M 2.96M 2.94M
Capital stock 5.90M 5.89M 4.37M 2.96M 2.94M
Retained earnings -334.13100M -329.60700M -405.76500M -439.50400M -698.32600M
Other liab - - - 9.35M 5.96M
Good will - - - - 0.00100M
Other assets - -0.00100M 0.00000M -0.00100M 6.52M
Cash 63.58M 143.25M 136.71M 97.70M 186.13M
Cash and equivalents - - - - -
Total current liabilities 145.75M 166.27M 155.14M 62.99M 49.35M
Current deferred revenue 96.80M 112.16M 110.33M 0.06M 0.30M
Net debt 56.32M -51.79000M -43.85500M -14.84800M -83.89600M
Short term debt 18.16M 13.23M 13.66M 12.96M 10.68M
Short long term debt 4.09M 4.84M 5.16M 5.09M 2.25M
Short long term debt total 119.90M 91.46M 92.85M 82.85M 102.24M
Other stockholder equity 437.44M 494.29M 522.78M 583.12M 934.70M
Property plant equipment - - - 107.90M 148.27M
Total current assets 236.24M 287.07M 233.00M 143.81M 225.43M
Long term investments 5.09M 7.52M 7.85M 8.79M 6.52M
Net tangible assets - - - 117.25M 219.44M
Short term investments 145.08M 117.06M 67.11M 7.91M 0.50M
Net receivables 22.20M 23.04M 23.13M 15.27M 29.63M
Long term debt 51.22M 43.99M 28.44M 20.53M 18.77M
Inventory - - - 21.77M 0.00000M
Accounts payable 17.28M 18.66M 19.07M 21.46M 23.76M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -33.31600M -39.53700M -36.69000M -28.60500M -18.02100M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 20.02M 11.60M 7.85M 0.00100M 0.00300M
Deferred long term asset charges - - - - -
Non current assets total 88.48M 96.48M 101.26M 117.41M 156.65M
Capital lease obligations 35.43M 42.63M 51.45M 57.23M 79.86M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -25.95000M -102.80800M -15.51000M -2.76100M 27.02M
Change to liabilities - - - 3.27M -0.58300M
Total cashflows from investing activities -29.57523M -102.62639M -15.51000M -2.76100M 7.28M
Net borrowings -16.19300M 7.14M 13.48M -6.60400M -12.46500M
Total cash from financing activities -16.19897M 89.80M 82.86M 1.15M 47.52M
Change to operating activities - - - -5.80600M 0.65M
Net income -67.80215M -36.69606M -116.83500M -98.68800M -125.10700M
Change in cash -79.67000M 6.54M 43.49M -92.42000M -55.51200M
Begin period cash flow 143.25M 136.71M 93.22M 185.64M 241.15M
End period cash flow 63.58M 143.25M 136.71M 93.22M 185.64M
Total cash from operating activities -40.13681M 22.10M -24.74600M -87.44400M -104.56200M
Issuance of capital stock 0.04M 82.82M 67.94M - 48.52M
Depreciation 20.12M 19.84M 18.52M 18.43M 16.57M
Other cashflows from investing activities - -1.26100M -14.43700M -0.44600M -0.00100M
Dividends paid 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change to inventory - - 0.00000M 0.00000M 1.60M
Change to account receivables -4.44471M -6.72210M 2.25M -3.18700M -5.83200M
Sale purchase of stock - - -0.56900M -0.56900M -
Other cashflows from financing activities -10.84746M -11.04246M -9.63500M 14.07M 11.47M
Change to netincome - - - 5.98M -2.77200M
Capital expenditures 2.37M 2.58M 1.07M 2.44M 19.74M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -41.72170M 53.57M -3.98600M -5.72300M -4.16300M
Stock based compensation 6.11M 3.17M 5.23M 6.04M 13.12M
Other non cash items 49.26M -14.61015M 71.95M -7.59800M -5.57000M
Free cash flow -42.50411M 19.52M -25.81900M -89.88500M -124.30500M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CLLS
Cellectis SA		 -0.16 5.37% 2.82 - - 5.18 5.46 4.05 -3.8964
NVO
Novo Nordisk A/S		 2.69 6.23% 45.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.60 3.69% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 15.16 3.36% 466.79 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.56 0.42% 612.50 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Cellectis SA

8, rue de la Croix Jarry, Paris, France, 75013

Key Executives

Name Title Year Born
Dr. Andre Choulika Ph.D. Co-Founder, CEO & Director 1965
Dr. David J. D. Sourdive Ph.D. Director, Deputy CEO, Exec. VP of CMC and Manufacturing 1967
Dr. Bing C. Wang M.B.A., Ph.D. Chief Financial Officer 1977
Valerie Cros Principal Financial Officer & Principal Accounting Officer NA
Mr. Jean Charles Epinat Chief Technological Officer NA
Dr. Philippe Duchateau Ph.D. Chief Scientific Officer 1963
Mr. Stephan Reynier M.Sc., MSc Chief Regulatory & Pharmaceutical Compliance Officer 1969
Ms. Marie-Bleuenn Terrier Gen. Counsel & Sec. of the Board of Directors 1982
Pascalyne Wilson Director of Communications NA
Ms. Kyung Nam-Wortman Exec. VP & Chief HR Officer 1970

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions